CY1121975T1 - Μεταλλαξεις του γονιδιου pik3ca στους ανθρωπινους καρκινους - Google Patents

Μεταλλαξεις του γονιδιου pik3ca στους ανθρωπινους καρκινους

Info

Publication number
CY1121975T1
CY1121975T1 CY20191100895T CY191100895T CY1121975T1 CY 1121975 T1 CY1121975 T1 CY 1121975T1 CY 20191100895 T CY20191100895 T CY 20191100895T CY 191100895 T CY191100895 T CY 191100895T CY 1121975 T1 CY1121975 T1 CY 1121975T1
Authority
CY
Cyprus
Prior art keywords
cancers
pik3ca
human cancer
gene mutations
pik3ca gene
Prior art date
Application number
CY20191100895T
Other languages
Greek (el)
English (en)
Inventor
Yardena Samuels
Victor Velculescu
Kenneth Kinzler
Bert Vogelstein
Original Assignee
The Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35056655&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1121975(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Johns Hopkins University filed Critical The Johns Hopkins University
Publication of CY1121975T1 publication Critical patent/CY1121975T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CY20191100895T 2004-03-02 2019-08-21 Μεταλλαξεις του γονιδιου pik3ca στους ανθρωπινους καρκινους CY1121975T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US54888604P 2004-03-02 2004-03-02
PCT/US2005/005193 WO2005091849A2 (en) 2004-03-02 2005-02-18 Mutations of the pik3ca gene in human cancers
EP12164819.0A EP2497836B1 (en) 2004-03-02 2005-02-18 Mutations of the PIK3CA gene in human cancers
EP15150891.8A EP2896703B1 (en) 2004-03-02 2005-02-18 Mutations of the PIK3CA gene in human cancers
EP05723277.9A EP1730303B1 (en) 2004-03-02 2005-02-18 Mutations of the pik3ca gene in human cancers

Publications (1)

Publication Number Publication Date
CY1121975T1 true CY1121975T1 (el) 2020-10-14

Family

ID=35056655

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100895T CY1121975T1 (el) 2004-03-02 2019-08-21 Μεταλλαξεις του γονιδιου pik3ca στους ανθρωπινους καρκινους

Country Status (14)

Country Link
US (6) US8026053B2 (https=)
EP (5) EP2497836B1 (https=)
JP (10) JP2007530017A (https=)
AU (2) AU2005227148B2 (https=)
CA (1) CA2560696C (https=)
CY (1) CY1121975T1 (https=)
DK (3) DK3556866T3 (https=)
ES (5) ES2437590T3 (https=)
HU (1) HUE045690T2 (https=)
LT (1) LT3296407T (https=)
PL (2) PL3296407T3 (https=)
PT (3) PT1730303E (https=)
SI (2) SI3296407T1 (https=)
WO (1) WO2005091849A2 (https=)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007530017A (ja) 2004-03-02 2007-11-01 ザ ジョンズ ホプキンス ユニバーシティ ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異
EP1849877A1 (en) * 2006-04-24 2007-10-31 Erasmus University Medical Center Rotterdam Replicative history of T-and B-cell subsets
WO2008109375A2 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting pik3c gene expression and uses thereof
GB2453173A (en) * 2007-09-28 2009-04-01 Dxs Ltd Polynucleotide primers
KR20100105648A (ko) 2007-12-03 2010-09-29 엔즌 파마슈티칼스, 인코포레이티드 Ｐｉｋ３ｃａ 발현 조절용 ｒｎａ 길항제 화합물
WO2009152346A2 (en) * 2008-06-11 2009-12-17 Intradigm Corporation Compositions comprising phosphoinositide 3-kinase sirna and methods of use thereof
CN101445832B (zh) * 2008-12-23 2011-09-14 广州益善生物技术有限公司 Pik3ca基因突变的检测探针、液相芯片及其检测方法
EP2553463B1 (en) 2010-03-26 2017-05-03 Hongzhi Zou Methods and materials for detecting colorectal neoplasm
AU2011329180A1 (en) * 2010-11-15 2013-05-02 Enzon Pharmaceuticals, Inc. Methods of treating cancers with HER3 and PIK3CA antisense oligonucleotides
JP2013545756A (ja) * 2010-11-16 2013-12-26 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッド 投与および治療方法
WO2012106175A1 (en) 2011-02-02 2012-08-09 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Trrap and grin2a mutations and use thereof for the diagnosis and treatment of melanoma
US9295673B2 (en) 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
ES2986436T3 (es) 2011-04-15 2024-11-11 Univ Johns Hopkins Sistema de secuenciación segura
US20140298493A1 (en) * 2011-07-28 2014-10-02 Somasekar Seshagiri PIK3CA H1047R Knock-In Non-Human Animal Breast Cancer Model
US9376715B2 (en) 2011-12-09 2016-06-28 Roche Molecular Systems, Inc Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene
WO2013177386A1 (en) 2012-05-24 2013-11-28 Abbvie Biotherapeutics Inc. Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy
CN102816839A (zh) * 2012-07-06 2012-12-12 杭州艾迪康医学检验中心有限公司 用于检测结直肠癌pik3ca基因热点突变位点的试剂盒
ES2886507T5 (es) 2012-10-29 2024-11-15 Univ Johns Hopkins Prueba de Papanicolaou para cánceres de ovario y de endometrio
EP2971075B1 (en) * 2013-03-13 2018-08-15 Roche Diagnostics GmbH Methods and compositions for detecting mutations in the human pi3kca (pik3ca) gene
CA2902916C (en) 2013-03-14 2018-08-28 Mayo Foundation For Medical Education And Research Detecting neoplasm
KR101501826B1 (ko) * 2013-04-05 2015-03-13 연세대학교 산학협력단 위암에 대한 예후 예측 모형의 제조방법
EP3027654B1 (en) * 2013-07-30 2019-09-25 Blueprint Medicines Corporation Pik3c2g fusions
CN120700143A (zh) 2014-03-31 2025-09-26 梅奥医学教育和研究基金会 检测结直肠赘生物
DK3198026T3 (da) * 2014-08-07 2020-01-20 Pharmassist Ltd Fremgangsmåde til bestemmelse af pik3ca-mutationsstatus i en prøve
US12391985B2 (en) 2014-08-07 2025-08-19 Pharmassist Ltd Method of determining PIK3CA mutational status in a sample
US10184154B2 (en) 2014-09-26 2019-01-22 Mayo Foundation For Medical Education And Research Detecting cholangiocarcinoma
CN104531854B (zh) * 2014-11-10 2017-01-18 中国人民解放军第三〇七医院 检测西妥昔单抗治疗转移性结直肠癌耐药的试剂盒
US10030272B2 (en) 2015-02-27 2018-07-24 Mayo Foundation For Medical Education And Research Detecting gastrointestinal neoplasms
US10435755B2 (en) 2015-03-27 2019-10-08 Exact Sciences Development Company, Llc Detecting esophageal disorders
US10689710B2 (en) * 2015-05-27 2020-06-23 Quest Diagnostics Investments Incorporated Methods for screening solid tumors for mutations
US11286531B2 (en) 2015-08-11 2022-03-29 The Johns Hopkins University Assaying ovarian cyst fluid
CN114574585A (zh) 2015-08-31 2022-06-03 梅约医药教育及研究基金会 检测胃肿瘤
RU2018123524A (ru) 2015-12-03 2020-01-09 Новартис Аг Фармацевтическая диагностика
RU2608960C1 (ru) * 2016-03-18 2017-01-27 Федеральное государственное бюджетное учреждение "Российский онкологический научный центр имени Н.Н. Блохина" Министерства здравоохранения Российской Федерации (ФГБУ "РОНЦ им. Н.Н. Блохина" Минздрава России) Клеточная линия crov Cel муцинозного рака яичников человека, предназначенная для разработки лечения таргетными препаратами
JP7481804B2 (ja) 2016-04-14 2024-05-13 マヨ ファウンデーション フォア メディカル エデュケーション アンド リサーチ 高度膵異形成の検出
US10370726B2 (en) 2016-04-14 2019-08-06 Mayo Foundation For Medical Education And Research Detecting colorectal neoplasia
JP7356349B2 (ja) 2017-02-28 2023-10-04 マヨ ファウンデーション フォア メディカル エデュケーション アンド リサーチ 前立腺癌検出
JP7224645B2 (ja) * 2017-03-30 2023-02-20 国立大学法人 東京大学 異なる複数の目的遺伝子の評価方法
CN111868260B (zh) 2017-08-07 2025-02-21 约翰斯霍普金斯大学 用于评估和治疗癌症的方法和材料
JP7067896B2 (ja) 2017-10-27 2022-05-16 シスメックス株式会社 品質評価方法、品質評価装置、プログラム、および記録媒体
JP7277460B2 (ja) 2017-11-30 2023-05-19 マヨ ファウンデーション フォア メディカル エデュケーション アンド リサーチ 乳癌の検出
EP4103748A4 (en) 2020-02-14 2024-03-13 The Johns Hopkins University METHOD AND MATERIALS FOR ASSESSING NUCLEIC ACIDS
CN111363827A (zh) * 2020-04-30 2020-07-03 北京和合医学诊断技术股份有限公司 用于检测pik3ca基因突变的引物组及其应用方法
DE102021126650A1 (de) 2021-10-14 2023-04-20 Rheinische Friedrich-Wilhelms-Universität Bonn, Körperschaft des öffentlichen Rechts Verfahren zur bestimmung der ansprechwahrscheinlichkeit einer malignen erkrankung auf eine behandlung mit einem pharmazeutischen hemmwirkstoff
CN116219015A (zh) * 2023-02-06 2023-06-06 中日友好医院(中日友好临床医学研究所) 基于pcr的dna中pik3ca基因突变检测试剂盒及检测方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5248671A (en) * 1989-02-15 1993-09-28 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oligonucleotides
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6274327B1 (en) 1992-04-13 2001-08-14 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
GB9208135D0 (en) 1992-04-13 1992-05-27 Ludwig Inst Cancer Res Polypeptides having kinase activity,their preparation and use
US5846824A (en) 1994-02-07 1998-12-08 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
US5846624A (en) * 1996-12-06 1998-12-08 The Standard Register Company Dual face pressure sensitive label
US6277563B1 (en) 1997-01-16 2001-08-21 The Regents Of The University Of California Genetic alterations associated with cancer
US7670767B1 (en) * 1997-01-16 2010-03-02 The Regents Of The University Of California Genetic alterations associated with cancer
US6558903B1 (en) 1999-06-30 2003-05-06 Millennium Pharmaceuticals, Inc. Kinases and uses thereof
ATE388226T1 (de) * 1999-08-27 2008-03-15 Novartis Vaccines & Diagnostic Chimerische antisense-oligonukleotide und zelltransfektions-zusammensetzungen davon
WO2001055301A2 (en) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
WO2002027028A1 (en) * 2000-09-28 2002-04-04 Atairgin Technologies, Inc. A method of determining tumor characteristics by determining abnormal copy number or expression level of lipid-associated genes
US20020142305A1 (en) 2001-03-27 2002-10-03 Koei Chin Methods for diagnosing and monitoring ovarian cancer by screening gene copy numbers
US20030135033A1 (en) * 2002-01-04 2003-07-17 Anke Klippel-Giese Compounds and methods for the identification and/ or validation of a target
JP2005533604A (ja) 2002-07-25 2005-11-10 アバンテック バスキュラー コーポレーション 治療薬を送達する装置とこれに関する方法
AU2004228668B2 (en) * 2003-04-03 2011-10-27 Park Funding, Llc PI-3 kinase inhibitor prodrugs
JP2007530017A (ja) 2004-03-02 2007-11-01 ザ ジョンズ ホプキンス ユニバーシティ ヒトの癌におけるｐｉｋ３ｃａ遺伝子の変異

Also Published As

Publication number Publication date
AU2005227148B2 (en) 2010-11-11
WO2005091849A3 (en) 2009-04-16
US8026053B2 (en) 2011-09-27
US20150079593A1 (en) 2015-03-19
US10704105B2 (en) 2020-07-07
EP3556866B1 (en) 2021-04-07
DK3296407T3 (da) 2019-08-19
EP3296407B1 (en) 2019-05-22
SI3296407T1 (sl) 2019-09-30
JP2013226141A (ja) 2013-11-07
SI1730303T1 (sl) 2013-12-31
PL1730303T3 (pl) 2014-04-30
PT3296407T (pt) 2019-08-23
EP3296407A1 (en) 2018-03-21
JP2012183065A (ja) 2012-09-27
DK1730303T3 (da) 2013-11-04
ES2869167T3 (es) 2021-10-25
US10787713B2 (en) 2020-09-29
EP1730303A2 (en) 2006-12-13
AU2011200600B2 (en) 2012-02-23
JP2020092711A (ja) 2020-06-18
ES2537633T3 (es) 2015-06-10
JP2020115891A (ja) 2020-08-06
CA2560696C (en) 2019-06-25
EP3556866A1 (en) 2019-10-23
US20090208505A1 (en) 2009-08-20
ES2663248T3 (es) 2018-04-11
JP5336620B2 (ja) 2013-11-06
EP1730303A4 (en) 2009-09-09
JP2022059046A (ja) 2022-04-12
JP2018153189A (ja) 2018-10-04
JP5894110B2 (ja) 2016-03-23
JP7304987B2 (ja) 2023-07-07
JP6695381B2 (ja) 2020-05-20
PL3296407T3 (pl) 2019-11-29
AU2011200600A1 (en) 2011-03-10
EP2896703A2 (en) 2015-07-22
EP2497836B1 (en) 2015-01-14
DK3556866T3 (da) 2021-05-03
CA2560696A1 (en) 2005-10-06
US20200024671A1 (en) 2020-01-23
JP2016041078A (ja) 2016-03-31
JP6250017B2 (ja) 2017-12-20
JP2007530017A (ja) 2007-11-01
PT3556866T (pt) 2021-04-30
JP6694543B2 (ja) 2020-05-13
JP6395917B2 (ja) 2018-09-26
JP2020028300A (ja) 2020-02-27
EP2896703B1 (en) 2017-10-25
JP2018023400A (ja) 2018-02-15
JP7001735B2 (ja) 2022-02-10
ES2437590T3 (es) 2014-01-13
WO2005091849A2 (en) 2005-10-06
US11549150B2 (en) 2023-01-10
US20180119231A1 (en) 2018-05-03
ES2869167T8 (es) 2022-01-20
JP7169315B2 (ja) 2022-11-10
EP1730303B1 (en) 2013-07-31
US20200248275A1 (en) 2020-08-06
ES2743125T3 (es) 2020-02-18
PT1730303E (pt) 2013-10-31
US20110319477A1 (en) 2011-12-29
EP2497836A1 (en) 2012-09-12
US10422006B2 (en) 2019-09-24
HUE045690T2 (hu) 2020-01-28
EP2896703A3 (en) 2015-10-21
LT3296407T (lt) 2019-09-10
AU2005227148A1 (en) 2005-10-06

Similar Documents

Publication Publication Date Title
CY1121975T1 (el) Μεταλλαξεις του γονιδιου pik3ca στους ανθρωπινους καρκινους
Khanmohammadi et al. Electrochemical biosensors for the detection of lung cancer biomarkers: A review
CY1124148T1 (el) Θεραπευτικοι παραγοντες για τη θεραπευτικη αγωγη ασθενειων που συνδεονται με ανεπιθυμητο κυτταρικο πολλαπλασιασμο
CY1112052T1 (el) Γονιδια και πολυπεπτιδια που σχετιζονται προς τους καρκινους ανθρωπινων κολον
NO20084546L (no) Diagnostikk og behandlinger for tumorer
CY1125190T1 (el) Χρηση ομαδων γονιδιων fgfr μεταλλαγματων στην εξακριβωση του εαν καρκινοπαθεις θα αποκρινονται σε αγωγη me fgfr αναστολεα
CY1119112T1 (el) K-ras μεταλλαξεις και θεραπεια anti-egfr αντισωματος
ATE194660T1 (de) Veraendertes gen bei menschlichem colorektalem- krebs
PL2223115T3 (pl) Sepraza jako marker nowotworowy
CY1118602T1 (el) Αντινεοπλασματικοι συνδυασμοι 4-ανιλινο-3-κυανοκινολινων και καπεσιταβινης
ATE538215T1 (de) Expressionsprofil von prostatakarzinom
EA200801037A1 (ru) Ингибиторы фосфатидилинозит-3-киназы и способы их применения
ATE470723T1 (de) Genexpressionsmarker für die prognose von brustkrebs
CY1115178T1 (el) Βιοδεικτες καρκινου
Seethala et al. Data set for the reporting of carcinomas of the major salivary glands: explanations and recommendations of the guidelines from the International Collaboration on Cancer Reporting
Eoh et al. Comparison of clinical features and outcomes in epithelial ovarian cancer according to tumorigenicity in patient-derived xenograft models
DE602004015626D1 (de) Bei brustkrebs
WO2007146668A3 (en) Use of imp3 as a prognostic marker for cancer
IL178042A0 (en) Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation
JP2014505877A5 (https=)
ATE512146T1 (de) Phenylharnstoffderivate als hemmstoffe von tyrosinkinasen zur behandlung von tumorerkrankungen
CY1114559T1 (el) Μεταλλαξεις του γονιδιου pik3ca στους ανθρωπινους καρκινους
Wong et al. The role of precision medicine in pancreatic cancer: challenges for targeted therapy, immune modulating treatment, early detection, and less invasive operations
WO2012003493A3 (en) Protein kinase ck2 gene mutations, amplifications and polymorphisms in human cancers and methods of use
EP1907842A4 (en) IDENTIFICATION PDGFR-ALPHA EXPRESSIVE NSCLC (NON-SMALL CELL LUNG CARCINOMA) TUMORS